Clinical Trial

A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the recommended dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-01.
Trial Details
NCT Number NCT06298071
Lead Sponsor Shanghai Institute Of Biological Products
Collaborators: The First Affiliated Hospital of Bengbu Medical University, The First Affiliated Hospital of Henan University of Science and Technology
Conditions Gout
Enrollment 36 participants
Start Date 2023-03-03
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-08